Licensing Trial Drugs To Foreign Firms A Failure For Indian Pharmas
This article was originally published in PharmAsia News
Executive Summary
The practice of Indian drug makers of licensing to foreign companies some of the molecules they have in clinical trials has not been a successful one for the licensing firms. Many of the licensed molecules have failed to survive late-stage trials, with a result of the foreign licensees simply abandoning them. Facing a shortage of finances necessary to carry on the work themselves, major Indian pharmas today focus on secondary research activities such as new delivery systems. (Click here for more